* preexisting liver disease * hypersensitivity to ivermectin * participants in other clinical trials for therapies against covid-19 * severe pneumonia * pregnant or breastfeeding women * concomitant use of warfarin, erdafitinib or quinidine * use of ivermectin in the 5 days prior to randomization * inability to obtain a blood sample needed to assess liver transaminases * elevation of transaminases \>1.5 times the normal level * participant whose first contact with the study personnel occurs between days 5 and 7 and at that time manifests significant and progressive resolution of covid-19 related signs and symptoms

* preexisting liver disease * hypersensitivity to ivermectin * participants in other clinical trials for therapies against covid-19 * severe pneumonia * pregnant or breastfeeding women * concomitant use of warfarin, erdafitinib or quinidine * use of ivermectin in the 5 days prior to randomization * inability to obtain a blood sample needed to assess liver transaminases * elevation of transaminases \>1.5 times the normal level * participant whose first contact with the study personnel occurs between days 5 and 7 and at that time manifests significant and progressive resolution of covid-19 related signs and symptoms

- preexisting liver disease - hypersensitivity to ivermectin - participants in other clinical trials for therapies against covid-19 - severe pneumonia - pregnant or breastfeeding women - concomitant use of warfarin, erdafitinib or quinidine - use of ivermectin in the 48 hours prior to randomization - inability to obtain a blood sample needed to assess liver transaminases - elevation of transaminases >1.5 times the normal level - participant whose first contact with the study personnel occurs between days 5 and 7 and at that time manifests significant and progressive resolution of covid-19 related signs and symptoms

- preexisting liver disease - hypersensitivity to ivermectin - participants in other clinical trials for therapies against covid-19 - severe pneumonia - pregnant or breastfeeding women - concomitant use of warfarin, erdafitinib or quinidine - use of ivermectin in the 48 hours prior to randomization - inability to obtain a blood sample needed to assess liver transaminases - elevation of transaminases >1.5 times the normal level - participant whose first contact with the study personnel occurs between days 5 and 7 and at that time manifests significant and progressive resolution of covid-19 related signs and symptoms